(Albany, US) DelveInsight has launched a new report on Epidermolysis Bullosa Epidemiology
DelveInsight’s ‘Epidermolysis Bullosa – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. To date, there is no treatment or cure for EB. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae.
Request for free sample page: – https://www.delveinsight.com/sample-request/epidermolysis-bullosa-epidemiology-forecast
Epidermolysis Bullosa Epidemiology
Epidermolysis Bullosa is of several types, and three major types of Epidermolysis bullosa includes Epidermolysis bullosa simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB). Assessments as per DelveInsight’s analysts show that the majority of cases of EB are Epidermolysis bullosa simplex, but similar trend is not followed by other countries. In 2017, there were 18,599 cases of EBS, 1,240 cases of JEB, and 4,960 cases of DEB in the United States. DEB is further divided as, recessive and dominant. Recessive DEB is more common than Dominant DEB.
Epidermolysis Bullosa Key Facts
Epidermolysis Bullosa Report Scope
Download free sample page: – https://www.delveinsight.com/sample-request/epidermolysis-bullosa-epidemiology-forecast
Table of content
1. Key Insights
2. Executive Summary of Epidermolysis Bullosa
3. Epidermolysis Bullosa: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Why should you buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/